Pyxis Oncology (PYXS) Capital Leases (2024 - 2025)
Pyxis Oncology (PYXS) reported Capital Leases of $23000.0 for Q4 2025, down 77.0% year-over-year from $100000.0 in Q4 2024, and down 46.51% quarter-over-quarter from $43000.0 in Q3 2025.
Pyxis Oncology (PYXS) Capital Leases (2024 - 2025) Analysis & Trends
Pyxis Oncology (PYXS) has 2 years of Capital Leases data on file, last reported at $23000.0 in Q4 2025.
- Capital Leases for Q4 2025 came in at $23000.0, down 77.0% year-over-year; the trailing twelve-month figure through Dec 2025 was $23000.0 (down 77.0% YoY), and the FY2025 annual result was $23000.0, down 77.0% from the prior year.
- Capital Leases fell to $23000.0 in Q4 2025 per PYXS's latest filing, from $43000.0 in the prior quarter.
- Over five years, Capital Leases peaked at $135000.0 in Q2 2024 and troughed at $23000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Pyxis Oncology | 125.84 Mn | 108.95 Mn | 8.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 23,000.00 |
| Sep 30, 2025 | 43,000.00 |
| Jun 30, 2025 | 62,000.00 |
| Mar 31, 2025 | 80,000.00 |
| Dec 31, 2024 | 100,000.00 |
| Sep 30, 2024 | 117,000.00 |
| Jun 30, 2024 | 135,000.00 |